Andeweg CS, Berg R, Staal JB et al. Patient-reported Outcomes After Conservative or Surgical Management of Recurrent and Chronic Complaints of Diverticulitis: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2016; 14(2): 183-190.
Balk EM, Adam GP, Cao W et al. Management of Colonic Diverticulitis. (AHRQ Comparative Effectiveness Reviews; No. 233). 2020.
Carabotti M, Annibale B, Severi C et al. Role of Fiber in Symptomatic Uncomplicated Diverticular Disease: A Systematic Review. Nutrients 2017; 9(2): 161.
Carter F, Alsayb M, Marshall JK et al. Mesalamine (5-ASA) for the prevention of recurrent diverticulitis. Cochrane Database Syst Rev 2017; (10): CD009839.
Iannone A, Ruospo M, Wong G et al. Mesalazine for People with Diverticular Disease: A Systematic Review of Randomized Controlled Trials. Can J Gastroenterol Hepatol 2018: 5437135.
Khan RM, Ali B, Hajibandeh S et al. Effect of mesalazine on recurrence of diverticulitis in patients with symptomatic uncomplicated diverticular disease: a meta-analysis with trial sequential analysis of randomized controlled trials. Colorectal Dis 2018; 20(6): 469-478.
Lahner E, Bellisario C, Hassan C et al. Probiotics in the Treatment of Diverticular Disease. A Systematic Review. J Gastrointestin Liver Dis 2016; 25(1): 79-86.
Leifeld L, Germer CT, Bohm S et al. S2k-Leitlinie Divertikelkrankheit/Divertikulitis. Z Gastroenterol 2014; 52(7): 663-710.
Morris AM, Regenbogen SE, Hardiman KM et al. Sigmoid diverticulitis: a systematic review. JAMA 2014; 311(3): 287-297.
Picchio M, Elisei W, Brandimarte G et al. Mesalazine for the Treatment of Symptomatic Uncomplicated Diverticular Disease of the Colon and for Primary Prevention of Diverticulitis: A Systematic Review of Randomized Clinical Trials. J Clin Gastroenterol 2016; 50 (Suppl 1): S64-69.
Van de Wall BJ, Stam MA, Draaisma WA et al. Surgery versus conservative management for recurrent and ongoing left-sided diverticulitis (DIRECT trial): an open-label, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol 2017; 2(1): 13-22.
IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.